News

Hosted on MSN1mon
Avoidable Cancers After Colonoscopy; Real-World Rinvoq Data; Drug Flops in IBS Trial
And Agomab's novel ALK5 inhibitor (AGMB-129) met its primary endpoint in a phase II trial of fibrostenosing Crohn's disease, the company announced. Tapering prednisolone reduced the risk of ...
pharmaphorum6d
Agomab raises $100m for Crohn’s drug, and other financings
Belgium-based Agomab will use some of the proceeds to fund a recently-started phase 2 trial of its lead ALK5 inhibitor AGMB-129 ... site biology at the gene and pathway level from a simple blood ...